Online inquiry

IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ5219MR)

This product GTTS-WQ5219MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor IX substitute gene. The antibody can be applied in Hemophilia B research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000133.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2158
UniProt ID P00740
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ5219MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2800MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-301
GTTS-WQ3187MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ8486MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA hu1124
GTTS-WQ13937MR IVTScrip™ mRNA-Anti-PDCD1, REGN-2810(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-2810
GTTS-WQ11891MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ13229MR IVTScrip™ mRNA-Anti-TNFRSF9, PF-05082566(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA PF-05082566
GTTS-WQ7764MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ4093MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BI-204
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW